Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Sheila Doggrell

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Procedures

Disorders

Chemicals & Drugs

Anatomy

Phenomena

Muscle Contraction

Concepts & Ideas

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
8
Nand, Vinita
5
Wanstall, Janet
3
Chen, Ying-Yu
3
Hancox, Jules
1
Hoberg, John
1
Homer, Kerry
1
Gambino, Agatha
1
Brown, Lindsay
1
Petcu, Eugen

Sign-in to see all Coauthors

Publications

TOP 3
Doggrell Sheila A
Is liraglutide or exenatide better in type 2 diabetes?
Doggrell Sheila A
Is zoledronic acid an anticancer drug?
Doggrell Sheila A
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Sheila Doggrell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Doggrell Sheila A
Is liraglutide or exenatide better in type 2 diabetes?
Expert opinion on pharmacotherapy 2009;10(16):2769-72.
2009: Doggrell Sheila A
Is zoledronic acid an anticancer drug?
Expert opinion on pharmacotherapy 2009;10(14):2387-90.
2009: Doggrell Sheila A
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Expert review of anticancer therapy 2009;9(9):1211-8.
2009: Doggrell Sheila A
Tesofensine--a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13.
Expert opinion on investigational drugs 2009;18(7):1043-6.
2009: Doggrell Sheila A
Telcagepant is a new oral treatment for migraine.
Expert opinion on pharmacotherapy 2009;10(9):1523-6.
2009: Doggrell Sheila A
Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes.
IDrugs : the investigational drugs journal 2009;12(5):309-17.
2009: Doggrell Sheila A
New findings with old drugs for osteoporosis.
Expert opinion on pharmacotherapy 2009;10(3):513-6.
2008: Doggrell Sheila A
Is rimonabant efficacious and safe in the treatment of obesity?
Expert opinion on pharmacotherapy 2008;9(15):2727-31.
2008: Doggrell Sheila A
Is tocilizumab an option for the treatment of arthritis?
Expert opinion on pharmacotherapy 2008;9(11):2009-13.
2008: Doggrell Sheila A
Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Expert opinion on pharmacotherapy 2008;9(9):1619-22.
2008: Doggrell Sheila A
The failure of torcetrapib: is there a case for independent preclinical and clinical testing?
Expert opinion on pharmacotherapy 2008;9(6):875-8.
2008: Doggrell Sheila A
New indications for topiramate: alcohol dependency and binge-eating disorder.
Expert opinion on pharmacotherapy 2008;9(5):869-73.
2008: Doggrell Sheila A
New horizons for zoledronic acid: results of the HORIZON trials in postmenopausal women with osteoporosis and after hip fracture.
Expert opinion on pharmacotherapy 2008;9(4):663-8.
2008: Doggrell Sheila A
Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
Expert opinion on pharmacotherapy 2008;9(3):405-20.
2008: Doggrell Sheila A
Celecoxib to prevent restenosis--results from the COREA-TAXUS trial.
Expert opinion on pharmacotherapy 2008;9(2):339-41.
2008: Doggrell Sheila A
Is sapropterin treatment suitable for all subjects with phenylketonuria?
Expert opinion on pharmacotherapy 2008;9(1):145-7.
2007: Doggrell Sheila A
Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?
Expert opinion on pharmacotherapy 2007;8(17):2903-15.
2007: Doggrell Sheila A
Does rosiglitazone increase cardiovascular outcomes?
Expert opinion on pharmacotherapy 2007;8(15):2665-9.
2007: Doggrell Sheila A
Cardiovascular and renal effects of nociceptin/orphanin FQ: a new mediator to target?
Current opinion in investigational drugs (London, England : 2000) 2007;8(9):742-9.
2007: Doggrell Sheila A
Clopidogrel use with stenting.
Expert opinion on pharmacotherapy 2007;8(9):1399-402.
2007: Doggrell S
Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
International journal of impotence research 2007;19(3):281-95.
2007: Doggrell Sheila A
Is fingolimod an advancement in the treatment of multiple sclerosis? KAPPOS L, ANTEL J, COMI G. et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 355:1124-1140.
Expert opinion on pharmacotherapy 2007;8(3):383-6.
2007: Doggrell Sheila A
Rosiglitazone: rosy news for a thiazolidinedione.
Expert opinion on pharmacotherapy 2007;8(2):265-8.
2007: Doggrell Sheila A
Misoprostol for the treatment of early pregnancy failure.
Current clinical pharmacology 2007;2(1):1-9.
2007: Doggrell Sheila A
Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide.
Reviews on recent clinical trials 2007;2(1):77-84.
2006: Doggrell Sheila A
Partial agonism at nicotinic receptors with varenicline--a new approach to smoking cessation.
Expert opinion on pharmacotherapy 2006;7(18):2599-603.
2006: Doggrell Sheila A
Sibutramine for obesity in adolescents.
Expert opinion on pharmacotherapy 2006;7(17):2435-8.
2006: Doggrell Sheila A
Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?
Expert opinion on pharmacotherapy 2006;7(15):2169-73.
2006: Doggrell Sheila A
Recent evidence of sustained benefit with exenatide in Type 2 diabetes.
Expert opinion on pharmacotherapy 2006;7(14):2003-6.
2006: Doggrell Sheila A
Natalizumab in multiple sclerosis: proceed with caution?
Expert opinion on pharmacotherapy 2006;7(12):1675-8.
2006: Doggrell Sheila A
After the failure of citalopram for depression, what next?
Expert opinion on pharmacotherapy 2006;7(11):1515-8.
2006: Doggrell Sheila A
Phosphoinositide 3-kinase-gamma as a target in rheumatoid arthritis and systemic lupus.
Expert opinion on therapeutic targets 2006;10(4):627-30.
2006: Doggrell Sheila A
Australian neuroscience in 2006--highlights from the scientific meeting.
Drug news & perspectives 2006;19(5):300-6.
2006: Doggrell Sheila A
Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
Expert opinion on pharmacotherapy 2006;7(9):1229-33.
2006: Doggrell Sheila A
Inhibition of RANKL: a new approach to the treatment of osteoporosis.
Expert opinion on pharmacotherapy 2006;7(8):1097-100.
2006: Doggrell Sheila A
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Reviews on recent clinical trials 2006;1(2):143-53.
2006: Doggrell Sheila
Pharmacology down under in 2005--focus on targets.
Drug news & perspectives 2006;19(4):233-41.
2006: Doggrell Sheila A
Is NXY-059 an advancement in the treatment of acute ischaemic stroke?
Expert opinion on pharmacotherapy 2006;7(7):965-8.
2006: Doggrell Sheila A
New targets in and potential treatments for cholesterol gallstone disease.
Current opinion in investigational drugs (London, England : 2000) 2006;7(4):344-8.
2006: Doggrell Sheila A
Is amlodipine the best initial monotherapy for hypertension?
Expert opinion on pharmacotherapy 2006;7(6):829-32.
2006: Doggrell Sheila A
'Simply stunning'--trastuzumab in HER2-positive breast cancer.
Expert opinion on pharmacotherapy 2006;7(5):631-4.
2006: Doggrell Sheila A
Bradykinin B2 receptors as a target in diabetic nephropathy.
Current opinion in investigational drugs (London, England : 2000) 2006;7(3):251-5.
2006: Doggrell Sheila; Singh Debbie
Intensive lipid lowering may not reduce major coronary events in people with previous myocardial infarction.
Evidence-based cardiovascular medicine 2006;10(1):61-3.
2006: Doggrell Sheila A
Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
Expert opinion on pharmacotherapy 2006;7(4):485-8.
2006: Doggrell Sheila A
Ceramide as a target in emphysema.
Expert opinion on therapeutic targets 2006;10(1):191-4.
2006: Doggrell Sheila A
Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease.
Expert opinion on investigational drugs 2006;15(2):99-106.
2006: Doggrell Sheila A
Sirolimus- or paclitaxel-eluting stents for coronary artery revascularisation.
Expert opinion on pharmacotherapy 2006;7(2):225-8.
2006: Doggrell Sheila A
Nitrone spin on cerebral ischemia.
Current opinion in investigational drugs (London, England : 2000) 2006;7(1):20-4.
2006: Doggrell Sheila A
Is exenatide advancing the treatment of type 2 diabetes?
Expert opinion on pharmacotherapy 2006;7(1):109-12.
2006: Doggrell Sheila A
Vascular medicine in Australia and Germany: highlights from the First International Conference in Vascular Medicine, held August 26-28, 2005, in Melbourne, Australia.
Timely topics in medicine. Cardiovascular diseases 2006;10():E7.
2006: Doggrell Sheila A
Inflammation, the key to much pathology. Highlights from the 7th World Congress on Inflammation, held August 20-24, 2005, in Melbourne, Australia.
Timely topics in medicine. Cardiovascular diseases 2006;10():E4.
2005: Doggrell Sheila A
Recent findings with docetaxel in postoperative treatment for breast cancer.
Expert opinion on pharmacotherapy 2005;6(16):2903-6.
2005: Doggrell Sheila A
Potential of growth hormone-releasing hormone antagonists (JV-1-36 and JV-1-42) for the treatment of brain tumours.
Expert opinion on investigational drugs 2005;14(12):1561-4.
2005: Doggrell Sheila A
Calmodulin kinase II as a target for inhibition in cardiac disease.
Expert opinion on therapeutic targets 2005;9(6):1319-21.
2005: Doggrell Sheila A
Highlights from the First International Conference in Vascular Medicine, held August 26-28, 2005, in Melbourne, Australia. Vascular medicine in Australia and Germany.
Drug news & perspectives 2005;18(9):595-600.
2005: Doggrell Sheila A
Pregabalin or morphine and gabapentin for neuropathic pain.
Expert opinion on pharmacotherapy 2005;6(14):2535-9.
2005: Doggrell Sheila A
Inflammation, the key to much pathology.
Drug news & perspectives 2005;18(8):531-9.
2005: Doggrell Sheila A
More support for high-dose atorvastatin in coronary artery disease.
Expert opinion on pharmacotherapy 2005;6(13):2365-8.
2005: Doggrell Sheila A
Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Expert opinion on pharmacotherapy 2005;6(12):2141-4.
2005: Doggrell Sheila A
Phosphodiesterase 5A as a target in cardiac disease.
Expert opinion on therapeutic targets 2005;9(5):1097-100.
2005: Doggrell Sheila A
Stabilisation of calstabin2--a new approach in sudden cardiac death.
Expert opinion on therapeutic targets 2005;9(5):955-62.
2005: Doggrell Sheila A
BG-9928 (Biogen Idec).
Current opinion in investigational drugs (London, England : 2000) 2005;6(9):962-8.
2005: Doggrell Sheila A
Taking the 20-HETE out of the cardiovascular system: the potential of 20-HETE synthesis inhibitors.
Current opinion in investigational drugs (London, England : 2000) 2005;6(9):901-6.
2005: Doggrell Sheila A
Clinical potential of nitric oxide-independent soluble guanylate cyclase activators.
Current opinion in investigational drugs (London, England : 2000) 2005;6(9):874-8.
2005: Doggrell Sheila A
Ximelagatran--recent comparisons with warfarin.
Expert opinion on pharmacotherapy 2005;6(11):1943-6.
2005: Doggrell Sheila A
Rho-kinase inhibitors show promise in pulmonary hypertension.
Expert opinion on investigational drugs 2005;14(9):1157-9.
2005: Doggrell Sheila A
CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction.
Expert opinion on pharmacotherapy 2005;6(10):1761-4.
2005: Doggrell Sheila A
Relating statin therapy to C-reactive protein levels.
Expert opinion on pharmacotherapy 2005;6(9):1597-600.
2005: Doggrell Sheila A
Neuromedin U--a new target in obesity.
Expert opinion on therapeutic targets 2005;9(4):875-7.
2005: Doggrell Sheila A
Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?
Expert opinion on investigational drugs 2005;14(8):1063-6.
2005: Doggrell Sheila A
New drugs being developed for the treatment of tuberculosis.
Expert opinion on investigational drugs 2005;14(7):917-20.
2005: Doggrell Sheila A
The nitrosterols--a step forward from the steroid anti-inflammatory drugs?
Expert opinion on investigational drugs 2005;14(7):823-8.
2005: Doggrell Sheila A
Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.
Expert opinion on pharmacotherapy 2005;6(8):1421-3.
2005: Doggrell Sheila A
RITA--a small-molecule anticancer drug that targets p53.
Expert opinion on investigational drugs 2005;14(6):739-42.
2005: Doggrell Sheila A
Aspirin and esomeprazole are superior to clopidogrel in preventing recurrent ulcer bleeding.
Expert opinion on pharmacotherapy 2005;6(7):1253-6.
2005: Doggrell Sheila A
Recent important trials of pharmacotherapy in Parkinson's disease.
Expert opinion on pharmacotherapy 2005;6(6):1025-8.
2005: Doggrell Sheila A
Has the controversy over the use of calcium channel blockers in coronary artery disease been resolved?
Expert opinion on pharmacotherapy 2005;6(5):831-4.
2005: Doggrell Sheila A
Berberine--a novel approach to cholesterol lowering.
Expert opinion on investigational drugs 2005;14(5):683-5.
2005: Doggrell Sheila A; Hancox Jules C
Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation.
Expert opinion on investigational drugs 2005;14(5):655-69.
2005: Doggrell Sheila A
Bradykinin B2 receptors--a target in diabetic nephropathy.
Expert opinion on therapeutic targets 2005;9(2):411-4.
2005: Doggrell Sheila A
Which drug combination for hormone-refractory prostate cancer?
Expert opinion on pharmacotherapy 2005;6(4):667-70.
2005: Doggrell Sheila A
Farnesoid X receptor agonism -- a new approach to the treatment of cholesterol gallstone disease.
Expert opinion on investigational drugs 2005;14(4):535-8.
2005: Doggrell Sheila A
New targets and new drugs down under in 2004.
Drug news & perspectives 2005;18(2):149-60.
2005: Doggrell S A
Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper.
Methods and findings in experimental and clinical pharmacology 2005;27(2):119-25.
2005: Doggrell Sheila A
Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
Expert opinion on investigational drugs 2005;14(3):339-42.
2005: Doggrell Sheila A
Conivaptan Yamanouchi.
Current opinion in investigational drugs (London, England : 2000) 2005;6(3):317-26.
2005: Doggrell Sheila A
Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
Current opinion in investigational drugs (London, England : 2000) 2005;6(3):242-4.
2005: Doggrell Sheila A
CHARMed - the effects of candesartan in heart failure.
Expert opinion on pharmacotherapy 2005;6(3):513-6.
2005: Doggrell Sheila A; Wanstall Janet C
Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors.
Canadian journal of physiology and pharmacology 2005;83(2):123-30.
2005: Doggrell Sheila A
NF-kappa B--a target in the inflammation of bone destruction.
Expert opinion on therapeutic targets 2005;9(1):191-3.
2005: Doggrell Sheila A
The safety of lumiracoxib when used in the treatment of arthritis.
Expert opinion on pharmacotherapy 2005;6(2):347-50.
2005: Doggrell Sheila A
A small-molecule lead compound for the treatment of Alzheimer's disease.
Expert opinion on investigational drugs 2005;14(2):199-201.
2005: Doggrell Sheila A
Recent advances in heart research.
Drug news & perspectives 2005;18(1):58-72.
2005: Doggrell Sheila A
BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia.
Expert opinion on investigational drugs 2005;14(1):89-91.
2005: Doggrell Sheila A
Fluoxetine--do the benefits outweigh the risks in adolescent major depression?
Expert opinion on pharmacotherapy 2005;6(1):147-50.
2005: Doggrell Sheila A
Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
Expert opinion on pharmacotherapy 2005;6(1):75-84.
2005: Wanstall Janet C; Homer Kerry L; Doggrell Sheila A
Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets.
Current vascular pharmacology 2005;3(1):41-53.
2004: Doggrell Sheila A
Calstabin2 - a new target in sudden cardiac death.
Expert opinion on therapeutic targets 2004;8(6):663-5.
2004: Doggrell Sheila A
Which drug combination for colorectal cancer?
Expert opinion on pharmacotherapy 2004;5(12):2621-4.
2004: Doggrell Sheila A
Alpha-lipoic acid, an anti-obesity agent?
Expert opinion on investigational drugs 2004;13(12):1641-3.
2004: Doggrell Sheila A
New drugs and new targets.
Drug news & perspectives 2004;17(9):615-32.
2004: Doggrell Sheila A
A neuroprotective derivative of erythropoietin that is not erythropoietic.
Expert opinion on investigational drugs 2004;13(11):1517-9.
2004: Doggrell Sheila A
Telmisartan - killing two birds with one stone.
Expert opinion on pharmacotherapy 2004;5(11):2397-400.
2004: Doggrell Sheila A
Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis.
Expert opinion on pharmacotherapy 2004;5(11):2209-20.
2004: Doggrell Sheila A
Focus on vascular pharmacology.
Drug news & perspectives 2004;17(8):543-52.
2004: Doggrell Sheila A
Inhibition of cardiac cytochrome P450: a new approach to cardiac ischaemia and reperfusion damage.
Expert opinion on therapeutic targets 2004;8(5):491-3.
2004: Doggrell Sheila A
Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease.
Expert opinion on investigational drugs 2004;13(10):1365-8.
2004: Doggrell Sheila A
Suramin: potential in acute liver failure.
Expert opinion on investigational drugs 2004;13(10):1361-3.
2004: Doggrell Sheila A
Is vasopressin-receptor antagonism an advancement in the treatment of heart failure?
Expert opinion on pharmacotherapy 2004;5(10):2181-4.
2004: Doggrell Sheila A
ETC-588 (Pfizer).
Current opinion in investigational drugs (London, England : 2000) 2004;5(9):993-9.
2004: Doggrell Sheila A
Tolvaptan (Otsuka).
Current opinion in investigational drugs (London, England : 2000) 2004;5(9):977-83.
2004: Doggrell Sheila A
Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents.
Expert review of cardiovascular therapy 2004;2(5):745-52.
2004: Doggrell Sheila A
Dawn of Aurora kinase inhibitors as anticancer drugs.
Expert opinion on investigational drugs 2004;13(9):1199-201.
2004: Doggrell Sheila A
Atorvastatin versus pravastatin: intensive versus moderate lipid lowering.
Expert opinion on pharmacotherapy 2004;5(9):2025-8.
2004: Doggrell Sheila A
After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia.
Expert opinion on pharmacotherapy 2004;5(9):1957-64.
2004: Doggrell Sheila A
Recent pharmacological advances in the treatment of preterm membrane rupture, labour and delivery.
Expert opinion on pharmacotherapy 2004;5(9):1917-28.
2004: Doggrell Sheila A
Is RGS-2 a new drug development target in cardiovascular disease?
Expert opinion on therapeutic targets 2004;8(4):355-8.
2004: Doggrell Sheila A
New drugs for the prevention and treatment of migraine: topiramate and BIBN 4096 BS.
Expert opinion on pharmacotherapy 2004;5(8):1837-40.
2004: Doggrell Sheila A
Intrathecal ziconotide for refractory pain.
Expert opinion on investigational drugs 2004;13(7):875-7.
2004: Doggrell Sheila A
Sarpogrelate: cardiovascular and renal clinical potential.
Expert opinion on investigational drugs 2004;13(7):865-74.
2004: Doggrell Sheila A
Recent important clinical trials of drugs in osteoporosis.
Expert opinion on pharmacotherapy 2004;5(7):1635-8.
2004: Doggrell Sheila A
Vascular biology support for the use of bevacizumab in colorectal cancer.
Expert opinion on investigational drugs 2004;13(6):703-5.
2004: Doggrell Sheila A
Sirolimus- versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery.
Expert opinion on pharmacotherapy 2004;5(6):1431-4.
2004: Doggrell Sheila A
The endothelin system and its role in acute myocardial infarction.
Expert opinion on therapeutic targets 2004;8(3):191-201.
2004: Doggrell Sheila A
Efalizumab for psoriasis?
Expert opinion on investigational drugs 2004;13(5):551-4.
2004: Doggrell Sheila A
Urotensin-II and the cardiovascular system--the importance of developing modulators.
Expert opinion on investigational drugs 2004;13(5):479-87.
2004: Doggrell Sheila A
Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
Expert opinion on pharmacotherapy 2004;5(5):1209-11.
2004: Doggrell Sheila A
Do vasopressin receptor type 2 antagonists have therapeutic potential in polycystic kidney diseases?
Expert opinion on investigational drugs 2004;13(4):431-4.
2004: Doggrell Sheila A; Hancox Jules C
Dronedarone: an amiodarone analogue.
Expert opinion on investigational drugs 2004;13(4):415-26.
2004: Doggrell Sheila A
Does the combination of alendronate and parathyroid hormone give a greater benefit than either agent alone in osteoporosis?
Expert opinion on pharmacotherapy 2004;5(4):955-8.
2004: Doggrell Sheila A
Pharmacology down under in 2003.
Drug news & perspectives 2004;17(2):149-59.
2004: Doggrell Sheila A
Amediplase. Menarini.
Current opinion in investigational drugs (London, England : 2000) 2004;5(3):344-7.
2004: Doggrell Sheila A
Can food intake be reduced with peptide YY3-36?
Expert opinion on investigational drugs 2004;13(3):285-7.
2004: Doggrell Sheila A;
Candesartan for the prevention and treatment of stroke - results of the SCOPE and ACCESS trials.
Expert opinion on pharmacotherapy 2004;5(3):687-90.
2004: Doggrell Sheila A; Wanstall Janet C
Vascular chymase: pathophysiological role and therapeutic potential of inhibition.
Cardiovascular research 2004;61(4):653-62.
2004: Doggrell Sheila A
Is everolimus useful in preventing allograft rejection and vasculopathy after heart transplant?
Expert opinion on investigational drugs 2004;13(2):161-3.
2004: Doggrell Sheila A
Cytokines, signaling and diseases - a pharmacologist's view.
Drug news & perspectives 2004;17(1):67-80.
2004: Doggrell Sheila A
The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease.
Expert opinion on investigational drugs 2004;13(1):69-72.
2004: Doggrell Sheila A
Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?
Expert opinion on pharmacotherapy 2004;5(1):205-8.
2003: Doggrell Sheila A
Recurrent hope for the treatment of preterm delivery.
Expert opinion on pharmacotherapy 2003;4(12):2363-6.
2003: Doggrell Sheila A
Are implantable cardioverter-defribrillators always superior to amiodarone?
Expert opinion on pharmacotherapy 2003;4(11):2111-4.
2003: Doggrell Sheila A
Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
Expert opinion on investigational drugs 2003;12(11):1855-9.
2003: Doggrell Sheila A
Cardiovascular research in Australia.
Drug news & perspectives 2003;16(8):540-50.
2003: Doggrell Sheila
Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?
Expert opinion on pharmacotherapy 2003;4(10):1857-60.
2003: Doggrell Sheila A; Evans Suzanne
Treatment of dementia with neurotransmission modulation.
Expert opinion on investigational drugs 2003;12(10):1633-54.
2003: Doggrell Sheila
Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?
Expert opinion on pharmacotherapy 2003;4(9):1605-7.
2003: Doggrell Sheila A
Present and future pharmacotherapy for osteoporosis.
Drugs of today (Barcelona, Spain : 1998) 2003;39(8):633-57.
2003: Doggrell Sheila A; Wanstall Janet C
Will chymase inhibitors be the next major development for the treatment of cardiovascular disorders?
Expert opinion on investigational drugs 2003;12(8):1429-32.
2003: Doggrell Sheila
Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?
Expert opinion on pharmacotherapy 2003;4(8):1431-3.
2003: Doggrell Sheila
Is AL-438 likely to have fewer side effects than the glucocorticoids?
Expert opinion on investigational drugs 2003;12(7):1227-9.
2003: Doggrell Sheila A; Hancox Jules C
Is timing everything? Therapeutic potential of modulators of cardiac Na(+) transporters.
Expert opinion on investigational drugs 2003;12(7):1123-42.
2003: Doggrell Sheila A
ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease.
Expert opinion on pharmacotherapy 2003;4(7):1185-8.
2003: Doggrell Sheila A
Does the melanin-concentrating hormone antagonist SNAP-7941 deserve 3As?
Expert opinion on investigational drugs 2003;12(6):1035-8.
2003: Doggrell Sheila A
Is natalizumab a breakthrough in the treatment of multiple sclerosis?
Expert opinion on pharmacotherapy 2003;4(6):999-1001.
2003: Doggrell Sheila A
Health and medical research down under in 2002.
Drug news & perspectives 2003;16(4):239-53.
2003: Doggrell Sheila A
ACE inhibitors versus diuretics: ALLHAT versus ANBP2.
Expert opinion on pharmacotherapy 2003;4(5):825-8.
2003: Doggrell Sheila A
The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation.
Expert opinion on investigational drugs 2003;12(5):805-23.
2003: Doggrell Sheila A
Warfarin and aspirin give more benefit than aspirin alone but also more bleeding after myocardial infarction.
Expert opinion on pharmacotherapy 2003;4(4):587-90.
2003: Doggrell Sheila
Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs?
Expert opinion on investigational drugs 2003;12(4):713-6.
2003: Thompson Rona; Doggrell Sheila; Hoberg John O
Potassium channel activators based on the benzopyran substructure: synthesis and activity of the C-8 substituent.
Bioorganic & medicinal chemistry 2003;11(8):1663-8.
2003: Doggrell Sheila A
ACE inhibitors or AT-1 antagonists - which is OPTIMAAL after acute myocardial infarction?
Expert opinion on pharmacotherapy 2003;4(3):407-9.
2003: Chen Y Y; Doggrell S A
Responsiveness, affinity constants and beta 2-adrenoceptor reserves for isoprenaline on portal veins from normo- and pre- and hypertensive rats.
Autonomic & autacoid pharmacology 2003;23(1):43-9.
2003: Doggrell Sheila A
Is levosimendan a breakthrough in the development of positive inotropes?
Expert opinion on pharmacotherapy 2003;4(2):289-92.
2003: Doggrell Sheila A
Reviparin as prophylaxis for thromboembolism after leg injury and hip replacement.
Expert opinion on pharmacotherapy 2003;4(2):285-8.
2003: Doggrell Sheila A
Losartan for LIFE in hypertension with left ventricular hypertrophy?
Expert opinion on pharmacotherapy 2003;4(1):115-8.
2002: Doggrell Sheila A
The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.
Expert opinion on investigational drugs 2002;11(11):1537-52.
2002: Doggrell Sheila A
Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?
Expert opinion on pharmacotherapy 2002;3(11):1543-56.
2002: Doggrell Sheila A
Functional beta1- and beta2-adrenoceptors in the left and right atrium of pre-hypertensive rats.
The Journal of pharmacy and pharmacology 2002;54(10):1407-12.
2002: Doggrell Sheila A
Effects of BDF 9198 on left ventricular contractility in advanced spontaneously hypertensive rats with heart failure.
The Journal of pharmacy and pharmacology 2002;54(8):1097-102.
2002: Doggrell Sheila A
TACE inhibition: a new approach to treating inflammation.
Expert opinion on investigational drugs 2002;11(7):1003-6.
2002: Doggrell Sheila A
Metformin & lifestyle intervention prevent Type 2 diabetes: lifestyle intervention has the greater effect.
Expert opinion on pharmacotherapy 2002;3(7):1011-3.
2002: Doggrell Sheila A
Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.
Expert opinion on pharmacotherapy 2002;3(7):1007-9.
2002: Doggrell Sheila A; Brown Lindsay
Present and future pharmacotherapy for heart failure.
Expert opinion on pharmacotherapy 2002;3(7):915-30.
2002: Doggrell Sheila A; Nand Vinita
Effects of dofetilide on cardiovascular tissues from normo- and hypertensive rats.
The Journal of pharmacy and pharmacology 2002;54(5):707-15.
2002: Doggrell Sheila A
Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?
Expert opinion on investigational drugs 2002;11(5):717-20.
2002: Doggrell Sheila A
The therapeutic potential of dopamine modulators on the cardiovascular and renal systems.
Expert opinion on investigational drugs 2002;11(5):631-44.
2002: Doggrell Sheila A
Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Expert opinion on pharmacotherapy 2002;3(5):625-8.
2002: Chen Ying-Yu; Doggrell Sheila A
Responsiveness, affinity constants and beta-adrenoceptor reserves for isoprenaline on aortae from normo-, pre- and hypertensive rats.
The Journal of pharmacy and pharmacology 2002;54(4):515-22.
2002: Doggrell Sheila A
Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.
Expert opinion on pharmacotherapy 2002;3(4):455-7.
2002: Doggrell Sheila A
Clopidogrel: a CURE in acute coronary syndromes?
Expert opinion on pharmacotherapy 2002;3(3):351-3.
2001: Doggrell S A
Pharmacology down under in 2001.
Drug news & perspectives 2001;14(10):630-40.
2001: Doggrell S A
Amiodarone -- waxed and waned and waxed again.
Expert opinion on pharmacotherapy 2001;2(11):1877-90.
2001: Doggrell S A
Pharmacotherapy of intermittent claudication.
Expert opinion on pharmacotherapy 2001;2(11):1725-36.
2001: Doggrell S A
Alteplase: descendancy in myocardial infarction, ascendancy in stroke.
Expert opinion on investigational drugs 2001;10(11):2013-29.
2001: Doggrell S A; Chan V
Using models in cardiovascular research: report on the satellite meeting to the International Congress of Physiological Sciences, Models in Cardiovascular Research.
Methods and findings in experimental and clinical pharmacology 2001;23(8):457-64.
2001: Doggrell S A; Chen Y Y
Responsiveness, affinity constants and receptor reserves for serotonin on aortae of aged normotensive and hypertensive rats.
The Journal of pharmacy and pharmacology 2001;53(10):1403-8.
2001: Doggrell S A
Statins in the 21st century: end of the simple story?
Expert opinion on investigational drugs 2001;10(9):1755-66.
2001: Doggrell S A
ReoPro rules: results from the 'Do Tirofiban and ReoPro Give Similar Efficacy Trial' (TARGET).
Expert opinion on pharmacotherapy 2001;2(9):1507-9.
2001: Doggrell S A; Nand V
Effects of tedisamil on cardiovascular tissues isolated from normo- and hypertensive rats.
Journal of cardiovascular pharmacology and therapeutics 2001;6(3):261-72.
2001: Doggrell S A
Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.
Expert opinion on pharmacotherapy 2001;2(7):1187-9.
2001: Doggrell S A
Triamcinolone: new and old indications.
Expert opinion on pharmacotherapy 2001;2(7):1177-86.
2001: Doggrell S A
Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators.
Expert opinion on investigational drugs 2001;10(6):1131-8.
2001: Doggrell S A
ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure.
Expert opinion on investigational drugs 2001;10(5):981-3.
2001: Doggrell S A; Brown L
The spironolactone renaissance.
Expert opinion on investigational drugs 2001;10(5):943-54.
2001: Doggrell S A
Moxonidine: some controversy.
Expert opinion on pharmacotherapy 2001;2(2):337-50.
2001: Doggrell S A; Chen Y Y
Potency, affinity constants and receptor reserves for noradrenaline and adrenaline on aortae from aged normo- and hypertensive rats.
The Journal of pharmacy and pharmacology 2001;53(2):205-12.
2001: Doggrell S A
Tedisamil: master switch of nature?
Expert opinion on investigational drugs 2001;10(1):129-38.
2000: Doggrell S A
Pharmacology down under in 2000.
Drug news & perspectives 2000;13(10):634-40.
2000: Nand V; Doggrell S A
Effects of azimilide on cardiovascular tissues from normo- and hypertensive rats.
Journal of cardiovascular pharmacology 2000;36(2):209-17.
2000: Doggrell S A; Brown L
D-Sotalol: death by the SWORD or deserving of further consideration for clinical use?
Expert opinion on investigational drugs 2000;9(7):1625-34.
2000: Nand V; Doggrell S A
Effects of clofilium on cardiovascular tissues from normo- and hypertensive rats.
Journal of autonomic pharmacology 2000;20(3):185-92.
1999: Doggrell S A; Wanstall J C; Gambino A
Functional effects of 4-aminopyridine (4-AP) on pulmonary and systemic vessels from normoxic control and hypoxic pulmonary hypertensive rats.
Naunyn-Schmiedeberg's archives of pharmacology 1999;360(3):317-23.
1999: Nand V; Doggrell S A
Effects of tetraethylammonium, 4-aminopyridine and bretylium on cardiovascular tissues from normo- and hypertensive rats.
The Journal of pharmacy and pharmacology 1999;51(5):631-40.
1999: Doggrell S A; Nand V; Henderson C J
The effects of lignocaine and tetrodotoxin on the action potentials and contractions of left ventricles from normo- and hypertensive rats.
General pharmacology 1999;32(4):429-37.
1999: Nand V; Doggrell S A
Effects of BDF 9148 on the action potentials and contractions of left ventricles from normo- and hypertensive rats.
Clinical and experimental pharmacology & physiology 1999;26(3):212-9.
1998: Doggrell S A; Henderson C J
The offset of beta-adrenoceptor antagonism of the responses of the rat right ventricle to isoprenaline.
Journal of autonomic pharmacology 1998;18(5):263-9.
1998: Doggrell S A; Brown L
Rat models of hypertension, cardiac hypertrophy and failure.
Cardiovascular research 1998;39(1):89-105.
1998: Doggrell S A; Petcu E B; Barnett C W
Affinity constants and beta-adrenoceptor reserves for isoprenaline on cardiac tissue from normotensive and hypertensive rats.
The Journal of pharmacy and pharmacology 1998;50(2):215-23.
1998: Doggrell S A; Liang L C
The relaxing effect of BDF 9148 on the KCl-contracted aorta isolated from normo- and hyper-tensive rats.
Naunyn-Schmiedeberg's archives of pharmacology 1998;357(2):126-32.
1997: Nand V; Doggrell S A; Barnett C W
Effects of veratridine on the action potentials and contractility of right and left ventricles from normo- and hypertensive rats.
Clinical and experimental pharmacology & physiology 1997;24(8):570-6.
1997: Doggrell S A; Mistry D N; Henderson C J
The effects of bromoacetylalprenololmenthane on the responses to isoprenaline of the left ventricle from normo-, prehyper- and hypertensive rats.
Journal of autonomic pharmacology 1997;17(3):183-90.
1996: Doggrell S A; Bishop B E
Veratridine augments and BDF 9148 attenuates the spontaneous contractile force of the rat portal vein.
The Journal of pharmacy and pharmacology 1996;48(8):820-4.
1996: Doggrell S A; Bishop B E
Effects of potassium channel blockers on the action potentials and contractility of the rat right ventricle.
General pharmacology 1996;27(2):379-85.
1995: Doggrell S A
Increase in affinity and loss of 5-hydroxytryptamine2A-receptor reserve for 5-hydroxytryptamine on the aorta of spontaneously hypertensive rats.
Journal of autonomic pharmacology 1995;15(5):371-7.
1995: Doggrell S A; Surman A J
Loss of maximum attenuation and receptor reserve for isoprenaline at the beta 2-adrenoceptors of the portal veins of hypertensive rats.
Journal of hypertension 1995;13(9):1023-9.
1995: Doggrell S A
Comparison of the attenuating effects of four beta-adrenoceptor agonists on rat isolated uterus and aorta.
Clinical and experimental pharmacology & physiology 1995;22(9):670-4.
1995: Doggrell S A; Bishop B E; Brosch S
The effects of veratridine and BDF 9148 on the action potentials and contractility of the rat right ventricle.
General pharmacology 1995;26(3):593-601.
1995: Doggrell S A; Bishop B E; Barnett C W
The effects of racemic, (+)- and (-)-pinacidil on the membrane potential of the rat aorta.
The Journal of pharmacy and pharmacology 1995;47(4):307-9.
1994: Doggrell S A; Surman A J
Functional beta-adrenoceptors in the left atrium of normotensive and hypertensive rats.
Journal of autonomic pharmacology 1994;14(6):425-36.
1994: Doggrell S; Hoey A; Brown L
Ion channel modulators as potential positive inotropic compound for treatment of heart failure.
Clinical and experimental pharmacology & physiology 1994;21(11):833-43.
1994: Doggrell S A
Characterization of the contractile responses to noradrenaline and adrenaline of aorta from normotensive and hypertensive rats.
General pharmacology 1994;25(5):1001-8.
1994: Bishop B E; Doggrell S A
The effects of racemic cromakalim, BRL 38226 and levcromakalim on the membrane potential of the rat aorta and of BRL 38226 on the contractile activity of the rat aorta and portal vein.
Journal of autonomic pharmacology 1994;14(2):99-108.
1993: Doggrell S A
Negative inotropic effect of pinacidil on the rat left atria.
The Journal of pharmacy and pharmacology 1993;45(11):1000-2.
1993: Surman A J; Doggrell S A
Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria.
Journal of cardiovascular pharmacology 1993;21(1):35-9.
1993: Doggrell S A
The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein.
Chirality 1993;5(1):8-14.
1992: Surman A J; Doggrell S A
Characterization of the antagonism with metoprolol, ICI 147,798, pindolol, mepindolol and bopindolol on the responses of the rat left atria to isoprenaline.
Naunyn-Schmiedeberg's archives of pharmacology 1992;346(6):657-64.
1992: Doggrell S A
The effects of labetalol and dilevalol on isolated cardiovascular preparations of the guinea-pig and rat.
The Journal of pharmacy and pharmacology 1992;44(12):1001-6.
1992: Doggrell S A
An analysis of the inhibitory effects of prazosin on the phenylephrine response curves of the rat aorta.
Naunyn-Schmiedeberg's archives of pharmacology 1992;346(3):294-302.
1992: Doggrell S A
Further analysis of the inhibitory effects of dihydroergotamine, cyproheptadine and ketanserin on the responses of the rat aorta to 5-hydroxytryptamine.
Journal of autonomic pharmacology 1992;12(4):223-36.
1992: Doggrell S A
Effects of (+/-)-, (+)- and (-)-celiprolol on the rat left atria and portal vein.
The Journal of pharmacy and pharmacology 1992;44(3):239-43.
1992: Bishop B E; Doggrell S A
Effects of potassium channel openers and calcium channel blockers on the force responses of the electrically driven rat right ventricle strip.
Journal of autonomic pharmacology 1992;12(1):5-14.
1991: Doggrell S A
Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein.
General pharmacology 1991;22(6):1169-77.
1990: Doggrell S A
Effects of bromoacetylalprenololmenthane (BAAM), an irreversible beta-adrenoceptor antagonist, on the rat isolated left atria and portal vein.
Journal of autonomic pharmacology 1990;10(6):333-44.
1990: Doggrell S A
Assessment of the beta 2 adrenoceptor and Ca2+ channel-blocking activity of drugs with the rat portal vein.
Journal of pharmacological methods 1990;24(2):145-56.
1990: Doggrell S A
Relaxant and beta 2-adrenoceptor blocking activities of (+/- )-, (+)- and (-)-pindolol on the rat isolated aorta.
The Journal of pharmacy and pharmacology 1990;42(6):444-6.
1990: Doggrell S A
The effects of (+/-)-, (+)- and (-)-celiprolol and bromoacetylalprenololmentane at the beta-adrenoceptors of rat isolated cardiovascular preparations.
The Journal of pharmacy and pharmacology 1990;42(5):319-24.
1990: Doggrell S A
The membrane stabilizing and beta 1-adrenoceptor blocking activity of (+)- and (-)-propranolol on the rat left atria.
General pharmacology 1990;21(5):677-80.
1989: Doggrell S A
The effects of beta-adrenoreceptor antagonists on the force responses of the electrically driven rat right ventricle strip to isoprenaline.
Journal of autonomic pharmacology 1989;9(4):265-77.
1989: Doggrell S A
Atenolol, bufuralol and prizidilol are dual antagonists of the responses of the electrically driven rat right ventricle strip to isoprenaline.
General pharmacology 1989;20(6):839-42.
1989: Doggrell S A
The inability of the rat aorta to relax to acetylcholine does not imply lack of a functional endothelium only.
General pharmacology 1989;20(4):395-8.
1989: Doggrell S A
The effects of atriopeptin and angiotensin on the rat right ventricle.
General pharmacology 1989;20(2):253-7.
1988: Doggrell S A
Relaxant and beta 2-adrenoceptor blocking activities of labetalol, dilevalol, amosulalol and KF-4317 on the rat isolated aorta.
The Journal of pharmacy and pharmacology 1988;40(11):812-5.
1988: Doggrell S A
No evidence for the differential antagonism of the initial fast and secondary slow contractile responses of the rat portal vein to phenylephrine, 5-hydroxytryptamine or methacholine.
Journal of autonomic pharmacology 1988;8(2):69-78.
1988: Doggrell S A
Simultaneous assessment of membrane-stabilizing and beta-adrenoceptor blocking activity of drugs with the rat isolated left atria.
Journal of pharmacological methods 1988;19(2):93-107.
1987: Doggrell S A
Differential antagonism of the initial fast and secondary slow contractile responses of the rat isolated aorta to 5-hydroxytryptamine by mianserin and ketanserin.
Journal of autonomic pharmacology 1987;7(2):157-64.

Sign-in to see more